187 related articles for article (PubMed ID: 38452438)
1. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.
de Boo LW; Jóźwiak K; Ter Hoeve ND; van Diest PJ; Opdam M; Wang Y; Schmidt MK; de Jong V; Kleiterp S; Cornelissen S; Baars D; Koornstra RHT; Kerver ED; van Dalen T; Bins AD; Beeker A; van den Heiligenberg SM; de Jong PC; Bakker SD; Rietbroek RC; Konings IR; Blankenburgh R; Bijlsma RM; Imholz ALT; Stathonikos N; Vreuls W; Sanders J; Rosenberg EH; Koop EA; Varga Z; van Deurzen CHM; Mooyaart AL; Córdoba A; Groen E; Bart J; Willems SM; Zolota V; Wesseling J; Sapino A; Chmielik E; Ryska A; Broeks A; Voogd AC; van der Wall E; Siesling S; Salgado R; Dackus GMHE; Hauptmann M; Kok M; Linn SC
ESMO Open; 2024 Mar; 9(3):102923. PubMed ID: 38452438
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
de Jong VMT; Wang Y; Ter Hoeve ND; Opdam M; Stathonikos N; Jóźwiak K; Hauptmann M; Cornelissen S; Vreuls W; Rosenberg EH; Koop EA; Varga Z; van Deurzen CHM; Mooyaart AL; Córdoba A; Groen EJ; Bart J; Willems SM; Zolota V; Wesseling J; Sapino A; Chmielik E; Ryska A; Broeks A; Voogd AC; Loi S; Michiels S; Sonke GS; van der Wall E; Siesling S; van Diest PJ; Schmidt MK; Kok M; Dackus GMHE; Salgado R; Linn SC
J Clin Oncol; 2022 Jul; 40(21):2361-2374. PubMed ID: 35353548
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
Martín M; Yoder R; Salgado R; Del Monte-Millán M; Álvarez EL; Echavarría I; Staley JM; O'Dea AP; Nye LE; Stecklein SR; Bueno C; Jerez Y; Cebollero M; Bueno O; García Saenz JÁ; Moreno F; Bohn U; Gómez H; Massarrah T; Khan QJ; Godwin AK; López-Tarruella S; Sharma P
Clin Cancer Res; 2024 May; 30(10):2160-2169. PubMed ID: 38466643
[TBL] [Abstract][Full Text] [Related]
6. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Adams S; Gray RJ; Demaria S; Goldstein L; Perez EA; Shulman LN; Martino S; Wang M; Jones VE; Saphner TJ; Wolff AC; Wood WC; Davidson NE; Sledge GW; Sparano JA; Badve SS
J Clin Oncol; 2014 Sep; 32(27):2959-66. PubMed ID: 25071121
[TBL] [Abstract][Full Text] [Related]
9. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
10. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
12. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
Pang J; Zhou H; Dong X; Wang S; Xiao Z
Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
[TBL] [Abstract][Full Text] [Related]
13. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
[TBL] [Abstract][Full Text] [Related]
14. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Candelaria RP; Spak DA; Rauch GM; Huo L; Bassett RL; Santiago L; Scoggins ME; Guirguis MS; Patel MM; Whitman GJ; Moulder SL; Thompson AM; Ravenberg EE; White JB; Abuhadra NK; Valero V; Litton J; Adrada BE; Yang WT
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S35-S41. PubMed ID: 34272161
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
16. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.
Tian T; Ruan M; Yang W; Shui R
Oncotarget; 2016 Jul; 7(28):44395-44405. PubMed ID: 27323808
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
20. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.
Van Bockstal MR; François A; Altinay S; Arnould L; Balkenhol M; Broeckx G; Burguès O; Colpaert C; Dedeurwaerdere F; Dessauvagie B; Duwel V; Floris G; Fox S; Gerosa C; Hastir D; Jaffer S; Kurpershoek E; Lacroix-Triki M; Laka A; Lambein K; MacGrogan GM; Marchiò C; Martin Martinez MD; Nofech-Mozes S; Peeters D; Ravarino A; Reisenbichler E; Resetkova E; Sanati S; Schelfhout AM; Schelfhout V; Shaaban A; Sinke R; Stanciu-Pop CM; van Deurzen CHM; Van de Vijver KK; Van Rompuy AS; Vincent-Salomon A; Wen HY; Wong S; Bouzin C; Galant C
Mod Pathol; 2021 Dec; 34(12):2130-2140. PubMed ID: 34218258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
